clinical trial · NCT07091630
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
argenx·phase3·recruiting·n = 160
Chronic Inflammatory Demyelinating PolyneuropathyCIDPChronic Inflammatory Demyelinating PolyradiculoneuropathyEmpasiprubart IVPlacebo IV
brief summary
The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emnergize
started
Sep 16, 2025
primary completion
Oct 7, 2027
completion
Jan 23, 2031
last updated
Mar 11, 2026
official title
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol